Sunday 18 October 2026
Export RLMD’s income statement to Excel — free account
Relmada Therapeutics, Inc.
RLMD Healthcare Biotechnology
In the quarter to June 2026, EPS grew 63.3% and free cash flow fell 50.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.10
0.10
−3.13%
Follow RLMD
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (55.66%) | (48.83%) | (94.05%) | (196.79%) |
+8 more TTM periods Free account |
|
| (51.57%) | (44.77%) | (82.08%) | (159.13%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(29.26%) | (26.47%) | (65.54%) | (581.23%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(0.41) | (0.49) | (1.16) | (1.20) | |
Free Cash Flow |
(45.99) | (42.79) | (45.79) | (39.99) | |
| Other line items | |||||
Cash ROIC |
(10.84%) | (9.45%) | (25.51%) | (171.25%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.74 | 0.73 | 0.80 | 0.71 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.41) | (0.49) | (1.16) | (1.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates